The Novel RARβ Isoform (β 5) is a Potential Target of Retinoids in Breast Cancer
Journal:
Current Cancer Drug Targets
Volume:
9
Page:
142-147
Author(s):
Konstantin Christov
Beyond Trastuzumab: Overcoming Resistance to Targeted HER-2 Therapy in Breast Cancer
Journal:
Current Cancer Drug Targets
Volume:
9
Page:
148-162
Author(s):
Philippe L. Bedard, Evandro de Azambuja and Fatima Cardoso
Role of the Akt Pathway in Prostate Cancer
Journal:
Current Cancer Drug Targets
Volume:
9
Page:
163-175
Author(s):
Paul L. de Souza, Pamela J. Russell and John Kearsley
Lipoamino Acid Prodrugs of Paclitaxel: Synthesis and Cytotoxicity Evaluation on Human Anaplastic Thyroid Carcinoma Cells
Journal:
Current Cancer Drug Targets
Volume:
9
Page:
202-213
Author(s):
R. Pignatello, D. Paolino, V. Panto, V. Pistara, M. G. Calvagno, D. Russo, G. Puglisi and M. Fresta
Nitric Oxide: Cancer Target or Anticancer Agent?
Journal:
Current Cancer Drug Targets
Volume:
9
Page:
214-236
Author(s):
Simone Mocellin
Targeted Therapy for Advanced Prostate Cancer: Inhibition of the PI3K/Akt/mTOR Pathway
Journal:
Current Cancer Drug Targets
Volume:
9
Page:
237-249
Author(s):
Todd M. Morgan, Theodore D. Koreckij and Eva Corey
Cancer Drug Development with the Help of Radiopharmaceuticals: Academic Experience
Journal:
Current Pharmaceutical Design
Volume:
15
Page:
950-956
Author(s):
Steven M. Larson
Radiopharmaceuticals for Oncology Drug Development: A Pharmaceutical Industry Perspective
Journal:
Current Pharmaceutical Design
Volume:
15
Page:
957-965
Author(s):
Philip S. Murphy and Mats Bergstrom
Defining Pharmacokinetics for Individual Patient Dosimetry in Routine Radiopeptide and Radioimmunotherapy of Cancer: Australian Experience
Journal:
Current Pharmaceutical Design
Volume:
15
Page:
966-982
Author(s):
J. Harvey Turner
Cancer Drug Development Using Glucose Metabolism Radiopharmaceuticals
Journal:
Current Pharmaceutical Design
Volume:
15
Page:
983-987
Author(s):
Y. Y. Sun and Y. Chen